Back

Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

Oslo, Norway, 9 October 2019 – Targovax ASA (OSE: TRVX), announces that clinical data on the company’s lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus which has been engineered to selectively infect and replicate in cancer cells, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held November 6-10, 2019, in Maryland, USA.

Title: A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma
Authors: Alexander N. Shoushtari, MD; Anthony J. Olszanski, MD, RPh; Thomas J. Hornyak, MD; Jedd D. Wolchok, MD, PhD; Sylvia Vetrhus; Karianne Risberg Handeland; Lukasz Kuryk, PhD; Magnus Jaderberg, MD;
Date: 9 November 2019
Time: 5:30 pm – 5:45 pm
Presenter: Dr. Alexander Shoushtari, Principal Investigator, MSKCC, NYC

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: moc.x1574135461avogr1574135461at@il1574135461ekrib1574135461.etan1574135461er1574135461

Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: on.mo1574135461cproc1574135461@mulg1574135461nit.s1574135461aerdn1574135461a1574135461

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumor-specific immune responses. In a phase I monotherapy trial, ONCOS-102 induced both local and systemic innate and adaptive immune activation, with associated clinical benefit. In an ongoing phase I trial, patients who have progressed on anti-PD1 checkpoint inhibitors and treated with ONCOS-102 in combination with Keytruda, demonstrated responses in three of nine patients (33% ORR) including one complete response. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around new year 2019-20.

 

This site uses cookies. But first we need your consent. More info.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close